Enveric Biosciences (ENVB) Property, Plant & Equipment (Net) Growth (1y) (2016 - 2026)
Enveric Biosciences (ENVB) Property, Plant & Equipment (Net) Growth (1y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PP&E (Net) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 24.71% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 12.77% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -99.85% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.07% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.70% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 10.87% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 70.79% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 19.14% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - | -66.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -55.13% |
| Dec 31, 2025 | -47.92% |
| Sep 30, 2025 | -46.55% |
| Jun 30, 2025 | -40.49% |
| Mar 31, 2025 | -40.90% |
| Dec 31, 2024 | -39.73% |
| Sep 30, 2024 | -31.80% |
| Jun 30, 2024 | -31.94% |
| Mar 31, 2024 | -29.22% |
| Dec 31, 2023 | -25.11% |
| Sep 30, 2023 | -24.38% |
| Jun 30, 2023 | -24.02% |
| Mar 31, 2023 | -17.75% |
| Dec 31, 2022 | 130.10% |
| Sep 30, 2022 | 407.19% |
| Sep 30, 2021 | 53.98% |
| Sep 30, 2020 | 40.16% |
| Jun 30, 2020 | 75.92% |
| Mar 31, 2020 | 100.60% |
| Dec 31, 2019 | 41.15% |